Expert Interview
Q2 update: Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM) with an academic cardiologist
Ticker(s): BBIO, ALNY, PFEInstitution: Stanford
- Cardiologist and physician Scientist at Amyloid Center at major academic center with a focus on Advanced Heart Failure and Transplant Cardiology.
- Currently manages 200 patients with ATTR amyloidosis and has published numerous papers on this topic.
- Research focuses on amyloidosis, transplant immunology, mechanical circulatory support, and non-ischemic cardiomyopathies.
How do you view Attruby compared to Vyndaqel?
Added By: wilson_adminHow do you view Amvuttra versus the oral options?
Added By: wilson_adminWhat are your thoughts on some of the investigational therapies, i.e. eplontersen and Nex-Z
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
